Reports Q4 revenue $38M, consensus $28.46M. "2022 was an exciting year for Arvinas as we transitioned into a late-stage development organization and laid the foundation for an important year of data readouts and trial initiations in 2023," said John Houston, Ph.D., president and chief executive officer at Arvinas. "Notably, the initiation of our Phase 3 monotherapy trial with ARV-471 in ER+/HER2- metastatic breast cancer marks our first registrational study and if successful, will lead to our first commercial product bringing an important new treatment option to patients. We are on-track to initiate our second and third Phase 3 trials – one in the first line setting with ARV-471 and one with bavdegalutamide in metastatic castrate resistant prostate cancer – in the second half of this year, further validating our novel PROTAC discovery engine platform."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Arvinas to Participate in Upcoming Investor Conferences
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Arvinas price target lowered to $65 from $100 at Truist
- Arvinas pullback a buying opportunity, says Capital One
